Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Cash (2020 - 2025)

Historic Change in Cash for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $25.7 million.

  • SAB Biotherapeutics' Change in Cash rose 41881.6% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year increase of 20024.38%. This contributed to the annual value of -$47.7 million for FY2024, which is 21480.99% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Change in Cash of $25.7 million as of Q3 2025, which was up 41881.6% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Change in Cash registered a high of $54.1 million during Q4 2023, and its lowest value of -$42.5 million during Q1 2024.
  • Its 5-year average for Change in Cash is $884964.5, with a median of -$2.0 million in 2023.
  • As far as peak fluctuations go, SAB Biotherapeutics' Change in Cash surged by 3384108.16% in 2021, and later crashed by 204071.64% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Change in Cash stood at $28.8 million in 2021, then crashed by 76.68% to $6.7 million in 2022, then surged by 706.3% to $54.1 million in 2023, then tumbled by 100.5% to -$273209.0 in 2024, then surged by 9518.61% to $25.7 million in 2025.
  • Its Change in Cash was $25.7 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$3.3 million in Q1 2025.